scholarly journals Circulating angiopoietin-like proteins in metabolic-associated fatty liver disease: a systematic review and meta-analysis

2021 ◽  
Vol 20 (1) ◽  
Author(s):  
Yani Ke ◽  
Shan Liu ◽  
Zheyuan Zhang ◽  
Jie Hu
Keyword(s):  
Liver Disease ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Meta Analysis ◽  
Healthy Control Group ◽  
Grade System ◽  
Cochrane Library ◽  
Control Group ◽  
Significant Difference ◽  
Healthy Control

Abstract Background Angiopoietin-like proteins (ANGPTLs) are closely related to insulin resistance and lipid metabolism, and may be a key in metabolic syndrome. Non-alcoholic fatty liver disease (NAFLD) (newly named metabolic-associated fatty liver disease (MAFLD)) is based on metabolic dysfunction. There may be some correlation between ANGPTLs and MAFLD, but the specific correlation is unclear. This study aims to explore the predictive role of ANGPTLs in MAFLD and its progression. Methods Seven databases (PubMed, EMBASE, Cochrane Library, CNKI, WANFANG, CBM and Clinicaltrials.gov) were searched with free terms and MeSH terms. The random-effects model was used to pool the data, and Standardized Mean Difference (SMD) and 95% confidence intervals (CI) were taken as the overall outcome. No language restrictions existed in the article selection. RevMan 5.3, Stata 16 and MetaXL software were applied to analyse the data and the GRADE system was utilized to assess the certainty of evidence. Results After reviewing 823 related articles, 13 studies (854 cases and 610 controls) met the inclusion criteria, and contributed to this meta-analysis. The results showed that circulating ANGPTL8 level was significantly elevated in the MAFLD group than in the healthy control group (SMD = 0.97 pg/mL, 95%CI: 0.77, 1.18). Conversely, there was no significant difference in the ANGPTL4 (SMD = 0.11 ng/mL, 95%CI: − 0.32, 0.54) and ANGPTL3 (SMD = − 0.95 ng/mL, 95%CI: − 4.38, 2.48) between the two groups. Subgroup analysis showed that: 1) the MAFLD group had significantly higher ANGPTL8 levels than the healthy control group in Asian and other races; 2) the ANGPTL8 levels in Body Mass Index (BMI) > 25 kg/m2 patients with MAFLD were higher than those in the healthy control group; 3) the higher ANGPTL8 levels were observed in moderate to severe MAFLD group than the healthy control group. Meta-regression demonstrated that BMI might effectively explain the high heterogeneity. No significant publication bias existed (P > 0.05). The certainty of evidence was assessed as very low by the GRADE system. Conclusions The ANGPTLs may be related to MAFLD. The increased ANGPTL8 level may be positively correlated with different situations of MAFLD, which may act as a potential indicator to monitor the development trends.

scholarly journals Preclinical Evidence of Berberine on Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis of Animal Studies

2021 ◽  
Vol 12 ◽  
Author(s):  
Sichen Ren ◽  
Xiao Ma ◽  
Ruilin Wang ◽  
Honghong Liu ◽  
Ying Wei ◽  
...  
Keyword(s):  
Systematic Review ◽  
Liver Disease ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Meta Analysis ◽  
Cochrane Library ◽  
Alcoholic Fatty Liver ◽  
Significant Downward Trend ◽  
Significant Difference ◽  
Alcoholic Fatty Liver Disease

As lifestyle and diet structure impact our health, non-alcoholic fatty liver disease (NAFLD) is prevalent all over the world. Some phytomedicines containing berberine (BBR) have been extensively used for centuries in Ayurvedic and traditional Chinese medicine. The goal of this systematic review is to investigate the preclinical evidence of BBR on NAFLD models. The following relevant databases, including Web of Science, PubMed, the Cochrane Library, and Embase, were retrieved from inception to May 2021. The content involved BBR on different animal models for the treatment of NAFLD. The SYstematic Review Center for Laboratory animal Experimentation (SYRCLE) Animal Experiment Bias Risk Assessment Tool was used to assess the methodological quality and RevMan 5.4 software was used to conduct the meta-analysis based on the Cochrane tool. A total of 31 studies involving 566 animals were included, of which five models and five animal breeds were reported. The results showed that TC, TG, ALT, AST, HDL-C, LDL-C, FBG, FINS, and FFA in the group treated with BBR were significantly restored compared with those in the model group. HOMA-IR had a significant downward trend, but the result was not significantly different (P = 0.08). The subgroup analysis of the different models and different animal breeds indicated that BBR could ameliorate the aforementioned indicator levels, although some results showed no significant difference. Finally, we summarized the molecular mechanisms by which berberine regulated NAFLD/NASH, mainly focusing on activating the AMPK pathway, improving insulin sensitivity and glucose metabolism, regulating mitochondrial function, reducing inflammation and oxidative stress, regulating cell death and ER stress, reducing DNA methylation, and regulating intestinal microenvironment and neurotoxicity. The preclinical evidence suggested that BBR might be an effective and promising drug for treating NAFLD/NASH. In addition, further studies with more well-designed researches are needed to confirm this conclusion.

scholarly journals Effect of Intermittent Fasting on Non-Alcoholic Fatty Liver Disease: Systematic Review and Meta-Analysis

2021 ◽  
Vol 8 ◽  
Author(s):  
Cong Yin ◽  
Zihan Li ◽  
Yulin Xiang ◽  
Hongbing Peng ◽  
Ping Yang ◽  
...  
Keyword(s):  
Liver Disease ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Lifestyle Modification ◽  
Meta Analysis ◽  
Cochrane Library ◽  
Intermittent Fasting ◽  
Alcoholic Fatty Liver ◽  
Significant Difference ◽  
Alcoholic Fatty Liver Disease

Background: Weight loss by lifestyle modification is the cornerstone therapy of non-alcoholic fatty liver disease (NAFLD). Intermittent fasting has shown favorable effects on body weight (BW) and relevant indicators of NAFLD in several reports.Objective: To estimate the effects of intermittent fasting on adults with NAFLD.Materials and methods: Literature searches were conducted on PubMed, EMBASE, Web of Science, Cochrane Library, and ClinicalTrials.gov from inception to May 10, 2021.Results: A total of six studies involving 417 patients with NAFLD were included. In the meta-analysis, there were significant differences in BW, body mass index (BMI), alanine aminotransferase (ALT), and aspartate transaminase (AST) between the control and fasting group. Up to now, there is no significant difference in triglycerides (TG), total cholesterol (TC), and other metabolic parameters between the two groups.Conclusions: Intermittent fasting is beneficial for weight management and liver enzyme improvement, but long-term feasibility and safety of intermittent fasting should be conducted in further studies.

scholarly journals Comparison of the Nutrition of Patients with and without Non-alcoholic Fatty Liver in Tehran

2018 ◽  
Vol 3 (4) ◽  
Author(s):  
Mahshid Akbari ◽  
Sima Zohari-Anboohi
Keyword(s):  
Liver Disease ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Statistical Power ◽  
Dietary Habits ◽  
Control Group ◽  
Case Group ◽  
Alcoholic Fatty Liver ◽  
Significant Difference ◽  
Alcoholic Fatty Liver Disease

Introduction: A high prevalence of non-alcoholic fatty liver disease is associated with obesity and lifestyle disorders. The present study was conducted to compare the nutritional pattern of patients with and without non-alcoholic fatty liver disease referred to the hospitals affiliated to Tehran University of Medical Sciences in 2017.Materials and Methods: The present case-control study was performed on a total of 300 outpatients and inpatients, aged 18–65 years. These patients were referred to the ultrasonography section of the hospitals, and those recruited in the study were selected by the convenience method of sampling. According to the results of ultrasonography, these subjects were divided into two groups: case (100 patients) and control (200 subjects for increasing the statistical power of study). The data were analyzed using the Statistical Package for the Social Sciences (version 19), descriptive statistics, and the Mann–Whitney test. P<0.05 was considered significant.Results: A significant difference was detected between the mean consumption of unhealthy foods in the case group as compared to the control group (P=0.001), while those with fatty liver reported a low average intake of fruits and vegetables with a significant difference (P=0.001).Conclusion: The results showed that patients with fatty liver complied with poor dietary habits as compared to individuals without the disease. 

scholarly journals NON-ALCOHOLIC FATTY LIVER DISEASE AND HYPERTENSION: CLINICAL VARIABILITY OF COMORBIDITY

2020 ◽  
Vol 7 (3) ◽  
Author(s):  
Anastasiia Rozhdestvenska ◽  
Oleg Babak ◽  
Natalia Zhelezniakova
Keyword(s):  
Liver Disease ◽  
Fatty Liver ◽  
Clinical Manifestation ◽  
Fatty Liver Disease ◽  
Hdl Cholesterol ◽  
Trigger Factor ◽  
Control Group ◽  
Alcoholic Fatty Liver ◽  
Significant Difference ◽  
Alcoholic Fatty Liver Disease

Introduction. Non-alcoholic fatty liver disease (NAFLD) is one of the most common chronic liver diseases; and considerable attention is paid to the comorbidity of NAFLD with hypertension (HT), which affects around one-third of the world's population. The combination of NAFLD with hypertension has been suggested to have a mutual potentiating effect, and hypertension affects the severity of NAFLD. The purpose: to study the features of the clinical manifestation of NAFLD in patients with hypertension. Materials and methods. The study included 115 patients with NAFLD at the stage of nonalcoholic steatohepatitis. The main group consisted of 63 patients with NAFLD and HT, the comparison group included 52 patients with isolated NAFLD, and the control group was composed of 20 healthy volunteers. The patients underwent anthropometric measurements, evaluation of biochemical markers of liver functional activity, lipid profile and carbohydrate metabolism changes, C-reactive protein (CRP) levels. Results. A significant increase in the proportion of patients with active complaints in the group of patients with NAFLD with HT (subjective signs of liver damage, manifestations of dyspeptic and asthenic syndrome) was detected. Significant differences were found in almost all anthropometric indicators in both groups of patients with NAFLD in comparison with the control group. The level of CRP had significant differences and was 7.90 mg/l (95% CI = 7.96-8.75 mg/l), 6.55 mg/l (95% CI = 6.47-7.57 mg/l) and 2.07 (95% CI = 1.83-2.85 mg/l) in patients with NAFLD and HT, isolated NAFLD and the control group, respectively (p <0.001). Fasting glucose levels were significantly higher in both groups of examined patients with NAFLD compared with controls. Significant differences were found in the levels of total cholesterol, VLDL cholesterol, HDL cholesterol and atherogenic factor in patients with NAFLD depending on concomitant HT. There was no significant difference between LDL cholesterol and triglycerides in the two groups of patients with NAFLD. Conclusions. Based on the obtained data, it can be stated that GC in patients with NAFLD determines important deviations in the clinical manifestation of the disease and can be considered as a trigger factor for the progression of NAFLD.

scholarly journals Association of Leptin and Adiponectin with Risk and Prognosis of Hepatocellular Carcinoma: A Combination of Traditional, Survival and Dose-response Meta-analysis

2020 ◽  
Author(s):  
Lilong Zhang ◽  
Qihang Yuan ◽  
Man Li ◽  
Dongqi Chai ◽  
Wenhong Deng ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Overall Survival ◽  
Meta Analysis ◽  
Healthy Control Group ◽  
Cochrane Library ◽  
Control Group ◽  
Linear Relationships ◽  
Increased Risk ◽  
Healthy Control ◽  
Carcinoma Risk

Abstract Background: The association between leptin, adiponectin levels and the risk as well as prognosis of hepatocellular carcinoma has been investigated by an increasing number of studies, but the results were controversial.Methods: A meta-analysis was performed to assess the correlation between leptin, adiponectin levels and risk and prognosis of hepatocellular carcinoma (CRD42020195882). Through June 14, 2020, PubMed, Cochrane Library, Embase databases, Clinicaltrials, and Opengrey were searched, including references of qualifying articles. Titles, abstracts, and main texts were reviewed by at least 2 independent readers. Stata 16.0 was used to calculate statistical data.Results: Thirty studies were included in this meta-analysis and results showed that hepatocellular carcinoma group had significantly higher leptin levels than the cancer-free control group (SMD = 1.83, 95% CI (1.09, 2.58), P = 0.000) , the healthy control group (SMD = 4.32, 95% CI (2.41, 6.24), P = 0.000) and the cirrhosis group (SMD = 1.85, 95% CI (0.70, 3.01), P = 0.002). Hepatocellular carcinoma group had significantly higher adiponectin levels than the healthy control group (SMD = 1.57, 95% CI (0.37, 2.76), P = 0.010), but no statistical difference compared with the cancer-free control group (SMD = 0.24, 95% CI (-0.35, 0.82), P = 0.430) and the cirrhosis group (SMD = -0.51, 95% CI (-1.30, 0.29), P= 0.213). The leptin rs7799039 polymorphism was associated with increased risk of hepatocellular carcinoma (G vs A: OR = 1.28, 95% CI (1.10, 1.48), P = 0.002). There were linear relationships between adiponectin levels and the risk of hepatocellular carcinoma (OR = 1.066, 95% CI (1.03, 1.11), P = 0.001). In addition, the results showed that high/positive expression of adiponectin was significantly related to lower overall survival in hepatocellular carcinoma patients (HR = 1.70, 95% CI (1.22, 2.37), P = 0.002); however, there was no significantly association between the leptin levels and overall survival (HR = 0.92, 95% CI (0.53, 1.59), P = 0.766).Conclusion: The study shows that high leptin levels are associated with a higher risk of hepatocellular carcinoma. Adiponectin levels are proportional to hepatocellular carcinoma risk, and are related to the poor prognosis.

scholarly journals Fetuin-A and Fetuin-B in Non-Alcoholic Fatty Liver Disease: A Meta-Analysis and Meta-Regression

2020 ◽  
Vol 17 (8) ◽  
pp. 2735 ◽  
Author(s):  
Xiongfeng Pan ◽  
Atipatsa C. Kaminga ◽  
Jihua Chen ◽  
Miyang Luo ◽  
Jiayou Luo
Keyword(s):  
Liver Disease ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Meta Analysis ◽  
Cochrane Library ◽  
Alcoholic Fatty Liver ◽  
Fetuin A ◽  
Nash Group ◽  
The Relationship ◽  
Alcoholic Fatty Liver Disease

The magnitude of the effect of fetuin-A and fetuin-B on non-alcoholic fatty liver disease (NAFLD) remains undefined. Therefore, the aim of this study was to synthesize previous findings to obtain a reliable estimation of this relationship. This study was registered in PROSPERO with the number CRD42019126314. Studies published not later than March 2019, examining the relationship between fetuin-A, fetuin-B, and NAFLD, were identified by a systematic search in the electronic databases of the Web of Science, PubMed, Embase, and Cochrane Library. Pooled estimates of standardized mean difference (SMD), calculated using the random-effects model in a meta-analysis, were applied to estimate the strength of the association between fetuin-A, fetuin-B, and NAFLD. Thirty publications were identified and analyzed based on specified inclusion criteria. Collectively, they consisted of 3800 NAFLD participants and 3614 controls. Compared with the controls, significant higher values of the fetuin-A (SMD = 0.83, 95% CI: 0.59 to 1.07, Z = 6.82, p < 0.001) and fetuin-B (SMD = 0.18, 95% CI: 0.02 to 0.33, Z = 2.27, p = 0.023) were observed in NAFLD patients. Meanwhile, in the subgroup analysis, the effect value of fetuin-A in the NASH group was significantly higher than that in the NAFL group (p = 0.036). The findings of this study suggest that elevated fetuin-A and fetuin-B may independently indicate the occurrence of NAFLD. Nevertheless, further research is needed to confirm these results.

scholarly journals The association of leptin and adiponectin with hepatocellular carcinoma risk and prognosis: a combination of traditional, survival, and dose-response meta-analysis

BMC Cancer ◽  
2020 ◽  
Vol 20 (1) ◽  
Author(s):  
Lilong Zhang ◽  
Qihang Yuan ◽  
Man Li ◽  
Dongqi Chai ◽  
Wenhong Deng ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Overall Survival ◽  
Meta Analysis ◽  
Healthy Control Group ◽  
Cochrane Library ◽  
Control Group ◽  
Linear Relationships ◽  
Increased Risk ◽  
Healthy Control ◽  
Carcinoma Risk

Abstract Background An increasing number of studies have focused on the association between leptin, adiponectin levels and the risk as well as the prognosis of hepatocellular carcinoma. However, the reported results are conflicting. Methods A meta-analysis was performed to assess the correlation between leptin, adiponectin levels and risk and prognosis of hepatocellular carcinoma (CRD42020195882). Through June 14, 2020, PubMed, Cochrane Library and EMBASE databases were searched, including references of qualifying articles. Titles, abstracts, and main texts were reviewed by at least 2 independent readers. Stata 16.0 was used to calculate statistical data. Results Thirty studies were included in this meta-analysis and results showed that hepatocellular carcinoma group had significantly higher leptin levels than the cancer-free control group (SMD = 1.83, 95% CI (1.09, 2.58), P = 0.000), the healthy control group (SMD = 4.32, 95% CI (2.41, 6.24), P = 0.000) and the cirrhosis group (SMD = 1.85, 95% CI (0.70, 3.01), P = 0.002). Hepatocellular carcinoma group had significantly higher adiponectin levels than the healthy control group (SMD = 1.57, 95% CI (0.37, 2.76), P = 0.010), but no statistical difference compared with the cancer-free control group (SMD = 0.24, 95% CI (− 0.35, 0.82), P = 0.430) and the cirrhosis group (SMD = − 0.51, 95% CI (− 1.30, 0.29), P = 0.213). The leptin rs7799039 polymorphism was associated with increased risk of hepatocellular carcinoma (G vs A: OR = 1.28, 95% CI (1.10, 1.48), P = 0.002). There were linear relationships between adiponectin levels and the risk of hepatocellular carcinoma (OR = 1.066, 95% CI (1.03, 1.11), P = 0.001). In addition, the results showed that high/positive expression of adiponectin was significantly related to lower overall survival in hepatocellular carcinoma patients (HR = 1.70, 95% CI (1.22, 2.37), P = 0.002); however, there was no significantly association between the leptin levels and overall survival (HR = 0.92, 95% CI (0.53, 1.59), P = 0.766). Conclusion The study shows that high leptin levels were associated with a higher risk of hepatocellular carcinoma. Adiponectin levels were proportional to hepatocellular carcinoma risk, and were related to the poor prognosis.

scholarly journals Incidence of hepatocellular carcinoma in patients with non-alcoholic fatty liver disease: A meta-analysis and meta-regression

2021 ◽  
Vol 108 (Supplement_4) ◽  
Author(s):  
L Orci ◽  
B Caballol ◽  
M Sanduzzi-Zamparelli ◽  
V Sapena ◽  
N Colucci ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Liver Cirrhosis ◽  
Liver Disease ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Meta Analysis ◽  
Sensitivity Analyses ◽  
Cochrane Library ◽  
Alcoholic Fatty Liver ◽  
Meta Regression

Abstract Objective Nonalcoholic fatty liver disease (NAFLD) may be a risk factor for hepatocellular carcinoma (HCC), but the extent of this association still needs to be addressed. Pooled-incidence rates of HCC across the disease spectrum of NAFLD have never been estimated by meta-analysis. Methods In this systematic review, we searched Web of Science, Embase, Pubmed, and the Cochrane library from January 1st, 1950 through July 30th, 2020. We included studies reporting on HCC incidence in patients with NAFLD. The main outcomes were pooled HCC incidences in patients with NAFLD at distinct severity stages. Summary estimates were calculated with random-effects models. Sensitivity analyses and meta-regression analyses were carried out to address heterogeneity. The protocol for this review was registered in Prospero (CRD42018092861). Results Eighteen studies, with a total of 470,404 patients were included. In patients with NAFLD at a stage earlier than liver cirrhosis, HCC incidence was of 0.03 per 100 person-years (PYs) (95% confidence interval 0.01-0.07, I2=98%). This rate rose to 3.78 per 100PYs (2.47-5.78, I2=93%) when considering studies that only included patients with liver cirrhosis. Among the latter patients, those undergoing regular HCC screening displayed an incidence of 4.62 per 100PYs (2.77-7.72, I2= 77%). Conclusion Patients with NAFLD-related liver cirrhosis have a risk of developing HCC similar to that reported for patients with cirrhosis from other etiologies. Evidence documenting the risk in patients with NASH or simple steatosis is limited, but HCC incidence in these populations may lie below thresholds used to recommend HCC screening. Well-designed prospective studies in these subsets of patients are needed.

scholarly journals Potential New Biomarkers Discovery of Early Nonalcoholic Fatty Liver Disease in Human by Liquid Chromatography–Mass Spectrometry

2020 ◽  
Author(s):  
Cheng Hu ◽  
Tao Wang ◽  
Jiaqi Zhang ◽  
Yuanye Jiang ◽  
Qin Cao
Keyword(s):  
Liver Disease ◽  
Fatty Liver ◽  
Nonalcoholic Fatty Liver Disease ◽  
Fatty Liver Disease ◽  
Early Stage ◽  
Control Group ◽  
Chinese Society ◽  
Nonalcoholic Fatty Liver ◽  
Significant Difference ◽  
Potential Biomarkers

Abstract BackgroundNAFLD is a common metabolic disorders disease which influenced 20~30% people. NAFLD can progress to cirrhosis, liver fibrosis and even liver cancer. Liver puncture is the gold standard. However, due to its trauma and possible complications, its clinical use is currently limited. Therefore, it is of great clinical significance and value to find a noninvasive biochemical index that can diagnose NAFLD early.ObjectiveOur aim was to identify the potential biomarkers in NAFLD people in early stage via untargeted metabolomics study.MethodsIn our research, From January to October 2019, 224 patients aged 18-55 were selected from the outpatient department and ward of gastroenterology department of Putuo Hospital in Shanghai.According to the NAFLD diagnostic criteria of the guidelines for diagnosis and treatment of nonalcoholic fatty liver disease (2018) formulated by the National workship on Fatty liver and alcoholic liver disease and Chinese Society on Hepatology, they were divided into the healthy control group and the experimental group.Besides,on the same day, the height, weight, waist, BMI, blood pressure and heart rate of patients were measured, and fasting blood was taken to obtain blood glucose,ALT, AST, TB, DB, TP, ALB, Che, ALP, γ - GT, TG, TC, HDL-C, LDL-C and other serum data.Serum samples were analyzed using LC/MS and data was processed by SIEVE software and simca-P to validate the potential biomarkers. The altered metabolites were identified by variable importance in projection value (VIP > 1) and ANOVA (p<0.01). The pathway analysis was performed by using MetaboAnalyst 4.0. In addition, our project has passed the review of ethics committee of Putuo Hospital Affiliated to Shanghai University of traditional Chinese medicine, and its ethics approval number is ptec-a-2018-49-1.ResultsThe serum biochemical indicators of early NAFLD patients showed no significant difference with NC (p>0.05). While there was significant difference of blood lipids indicators between NAFLD and NC (p<0.001). Finally, 55 metabolites were identified and the AUC of ROC curve results showed that new identified biomarkers owned high predictability and reliability. ConclusionIt is found that 15 metabolites in serum were of great diagnostic value in early NAFLD patients. AUC of these biomarkers (>0.9) were much higher than clinical indicators (0.770). This may be worth further research in the clinic.

scholarly journals Association Between Helicobacter Pylori Infection and Non-alcoholic Fatty Liver Disease, Hepatic Adipose Deposition and Stiffness in Southwest China

2021 ◽  
Vol 8 ◽  
Author(s):  
Ying Liu ◽  
Dongyu Li ◽  
Yuping Liu ◽  
Ping Shuai
Keyword(s):  
Helicobacter Pylori ◽  
Liver Disease ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Liver Steatosis ◽  
Liver Stiffness ◽  
Control Group ◽  
Alcoholic Fatty Liver ◽  
Significant Difference ◽  
H Pylori

Background: Both nonalcoholic fatty liver disease (NAFLD) and Helicobacter pylori (H. pylori) infection have high prevalence worldwide, and the relationship between both remains controversial. We try to investigate whether H. pylori infection is associated with NAFLD and increased liver fat deposition and stiffness in this cross-sectional study.Methods: The physical examination data of 5,665 subjects were obtained from February 2018 to June 2019 in this study. Clinical and biochemical data were collected. NAFLD was diagnosed using abdominal color Doppler ultrasonography. Liver steatosis and stiffness were understood by two parameters of transient elastography (TE): fat attenuation parameter (FAP) and liver stiffness measurement (LSM). H. pylori infection was determined using the 13C urea breath tests.Results: The total prevalence of NAFLD and H. pylori infection was 30.2 and 37.0%, respectively. In men, the prevalence of NAFLD and the levels of FAP and LSM in H. pylori-positive group were significantly higher than H. pylori-negative group (all p &lt; 0.01), but no significant difference was found in women. In men, the infection rate of H. pylori in NAFLD group and LSM ≥ 7.4 kPa group was significantly higher than control group. Multivariate logistic regression analysis revealed that H. pylori infection was not independently associated with NAFLD and FAP ≥ 240 dB/m. However, H. pylori infection was associated with LSM ≥ 7.4 kPa in men.Conclusions: Our study suggests that H. pylori infection is not significantly associated with NAFLD and elevated liver steatosis, whereas it may be the risk factor of elevated liver stiffness in men.

Sign in / Sign up

Export Citation Format

Share Document